Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan A Grupp

Showing results (181-190 of 238) with videos related to

Pageof 24
Sort By:
Nature|September 25, 2024
Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remissionZhiliang Bai, Bing Feng, Susan E McClory, et al.
The Journal of Clinical Investigation|August 30, 2016
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapiesMarco Ruella, David M Barrett, Saad S Kenderian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2021
Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical TrialStephan Kadauke, Regina M Myers, Yimei Li, et al.
Blood Cancer Discovery|January 12, 2022
Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic LeukemiaMichael A Pulsipher, Xia Han, Shannon L Maude, et al.
Blood Advances|November 19, 2019
CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapyVinodh Pillai, Kavitha Muralidharan, Wenzhao Meng, et al.
Cancer Discovery|February 1, 2020
Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell DysfunctionNathan Singh, Yong Gu Lee, Olga Shestova, et al.
Nature Communications|September 8, 2022
Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcomaAlexandra Gyurdieva, Stefan Zajic, Ya-Fang Chang, et al.
Blood Advances|August 25, 2021
Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphomaKaren Thudium Mueller, Stephan A Grupp, Shannon L Maude, et al.
Cell Cycle (Georgetown, Tex.)|November 22, 2017
Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignanciesVarun V Prabhu, Mala K Talekar, Amriti R Lulla, et al.
Haematologica|November 27, 2025
Hematopoietic cell transplantation after CD19-directed CAR T-cell therapy for remission consolidation or relapse treatment in pediatric acute lymphoblastic leukemiaRegina M Myers, Yimei Li, Hongyan Liu, et al.
Pageof 24

Showing results (181-190 of 238) with videos related to

Sort By:
Pageof 24
Nature|September 25, 2024
Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remissionZhiliang Bai, Bing Feng, Susan E McClory, et al.
The Journal of Clinical Investigation|August 30, 2016
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapiesMarco Ruella, David M Barrett, Saad S Kenderian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2021
Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical TrialStephan Kadauke, Regina M Myers, Yimei Li, et al.
Blood Cancer Discovery|January 12, 2022
Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic LeukemiaMichael A Pulsipher, Xia Han, Shannon L Maude, et al.
Blood Advances|November 19, 2019
CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapyVinodh Pillai, Kavitha Muralidharan, Wenzhao Meng, et al.
Cancer Discovery|February 1, 2020
Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell DysfunctionNathan Singh, Yong Gu Lee, Olga Shestova, et al.
Nature Communications|September 8, 2022
Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcomaAlexandra Gyurdieva, Stefan Zajic, Ya-Fang Chang, et al.
Blood Advances|August 25, 2021
Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphomaKaren Thudium Mueller, Stephan A Grupp, Shannon L Maude, et al.
Cell Cycle (Georgetown, Tex.)|November 22, 2017
Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignanciesVarun V Prabhu, Mala K Talekar, Amriti R Lulla, et al.
Haematologica|November 27, 2025
Hematopoietic cell transplantation after CD19-directed CAR T-cell therapy for remission consolidation or relapse treatment in pediatric acute lymphoblastic leukemiaRegina M Myers, Yimei Li, Hongyan Liu, et al.
Pageof 24